ClearEndoclip Versus EZ Clip for Upper Gastrointestinal Ulcer Bleeding

NCT ID: NCT04536428

Last Updated: 2020-09-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

176 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-24

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We are going to conduct a comparative study to analyze the clinical effectiveness and user convenience of EZ clips that have been used in upper gastrointestinal ulcer bleeding and newly developed clip (ClearEndoclip, FineMedix, Taegu) in Korea.

1\) Research hypothesis and purpose

* This study was designed to prove the hypothesis that the hemostatic effect of newly developed endoscopic clip (ClearEndoclip, FineMedix, Taegu, Korea) is not inferior to that of EZ clip (Olympus, Tokyo, Japan) in the treatment of hemostasis for patients who visited the upper gastrointestinal ulcer bleeding.
* This study was designed as a multi-center (9 institutions), open-labelled, randomized comparative clinical trial (1:1 ratio).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Design of this study

1. Stratified randomization is performed, and the variable used for stratification is the patient's age (65 years or older, 65 years or less).
2. The existing clip (control) and the domestic clip (experimental group) are divided by the block size randomization method of size 4 for each floor.
2. Patients and Methods

1. inclusion criteria

* Men and women aged 20 to 80
* The patients who came to the emergency room due to upper gastrointestinal bleeding with as follows: peptic ulcer with acute bleeding or protruding vascular exposure (Forrest class Ia-IIa), anastomotic vascular ulcer bleeding, bleeding from endoscopic submucosal dissection or endoscopic mucosal resection site after 24 hours
* American Society of Anesthesiologist (ASA) Physical Status 1 - 3
* Patients with adequate patient compliance and adequate geographical distance for follow-up. character
2. exclusion criteria

* Patients with gastrointestinal bleeding who are not recommended to clip Bleeding from a malignant tumor Hemorrhagic gastritis Angiodysplasia variceal bleeding
* Bleeding during endoscopic submucosal dissection or endoscopic mucosal resection
* Patients with insufficient clinical information
* Pregnant or lactating patients
* Patients or guardians who have not obtained informed consent
3. The number of patients

* The number of subjects was calculated based on a non-inferiority study

* The reported rate of rebleeding after hemostasis using the conventional hemoclip: about 5%.
* 2.5% one-sided test, 80% power, and non-inferiority limit set to 10%

* 75 subjects are required for each group, and 83 subjects are required if the drop rate is assumed to be 10%.
4. Methods

* After completing an informed consent form to the subjects who wish to participate in the study at the time of visit, basic clinical variables are checked.
* First endoscopic hemostasis is performed. In this time, EZ clip is used for the subjects assigned to the control group, and ClearEndoclip is used for the subjects assigned to the experimental group to target blood vessels in the ulcer. At the same time, clinical parameters related to hemostasis are recorded.
* After hemostasis is performed, rebleeding and complications are tracked up to 30 days after the procedure.
5. Variables to be collected

* At the time of visit: age, gender, height, weight, drug use (anticoagulant/antiplatelet agents, NSAIDs, steroids), underlying diseases (cirrhosis, diabetes, end-stage renal failure, heart disease, lung disease), hematological data, hemoglobin, Complete Rockall score
* At the time of primary endoscopic hemostasis: location of ulcer, size of ulcer, size of exposed blood vessel (based on 2mm), forrest classification, total number of clips used, number of failed clips, usage and usage of epinephrine, procedure time (minutes) , Clip hemostasis success, treatment after clip hemostasis failure
* After hemostasis: rebleeding (within 7 days), number of clips and bleeding from the follow-up endoscope after 48 hours, death within 30 days, ICU hospitalization date, total hospitalization date, complications of hemostasis, Helicobacter pylori

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peptic Ulcer Hemorrhage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ClearEndoclip

This arm is a group in whom ClearEndoclip would be used for the treatment of bleeding.

Group Type EXPERIMENTAL

Endoscopic hemostasis with clip

Intervention Type DEVICE

This intervention is performed as the following orders.

* The tip of endoscope is accessed to a bleeding site.
* The accurate visualization of bleeding site is done.
* A sheath of delivery system of clip is inserted through a working channel of endoscope.
* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.
* The both ends of clip are placed on both sides of a bleeding site.
* If bleeding is still continued, additional placements of clip are tried until bleeding stops.

EZ clip

This arm is a group in whom EZ clip would be used for the treatment of bleeding.

Group Type ACTIVE_COMPARATOR

Endoscopic hemostasis with clip

Intervention Type DEVICE

This intervention is performed as the following orders.

* The tip of endoscope is accessed to a bleeding site.
* The accurate visualization of bleeding site is done.
* A sheath of delivery system of clip is inserted through a working channel of endoscope.
* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.
* The both ends of clip are placed on both sides of a bleeding site.
* If bleeding is still continued, additional placements of clip are tried until bleeding stops.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endoscopic hemostasis with clip

This intervention is performed as the following orders.

* The tip of endoscope is accessed to a bleeding site.
* The accurate visualization of bleeding site is done.
* A sheath of delivery system of clip is inserted through a working channel of endoscope.
* The end of clip is opened in front of the bleeding site. If needed, clip could be rotated to adjust to a bleeding target.
* The both ends of clip are placed on both sides of a bleeding site.
* If bleeding is still continued, additional placements of clip are tried until bleeding stops.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 20 to 80
* The patients who came to the emergency room due to upper gastrointestinal bleeding with as follows: peptic ulcer with acute bleeding or protruding vascular exposure (Forrest class Ia-IIa), anastomotic vascular ulcer bleeding, bleeding from endoscopic submucosal dissection or endoscopic mucosal resection site after 24 hours
* American Society of Anesthesiologist (ASA) Physical Status 1 - 3
* Patients with adequate patient compliance and adequate geographical distance for follow-up. character

Exclusion Criteria

* Patients with gastrointestinal bleeding who are not recommended to clip Bleeding from a malignant tumor Hemorrhagic gastritis Angiodysplasia variceal bleeding
* Bleeding during endoscopic submucosal dissection or endoscopic mucosal resection
* Patients with insufficient clinical information
* Pregnant or lactating patients
* Patients or guardians who have not obtained informed consent
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Keimyung University Dongsan Medical Center

OTHER

Sponsor Role collaborator

Korea University Anam Hospital

OTHER

Sponsor Role collaborator

National Cancer Center, Korea

OTHER_GOV

Sponsor Role collaborator

Nowon Eulji Medical Center

UNKNOWN

Sponsor Role collaborator

Pusan National University Hospital

OTHER

Sponsor Role collaborator

Wonju Severance Christian Hospital

OTHER

Sponsor Role collaborator

Inha University Hospital

OTHER

Sponsor Role collaborator

Presbyterian medical center

UNKNOWN

Sponsor Role collaborator

Ajou University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sun Gyo Lim, MD

Associate professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sun Gyo Lim

Role: PRINCIPAL_INVESTIGATOR

Department of Gastroenterology, Ajou University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sun Gyo Lim

Suwon, Gyeonggi-do, South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AJIRB-DEV-DE2-20-148

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.